VERAXA Biotech AG (NASDAQ: VRXA) is expanding its use of human-relevant testing methods across its oncology research programs, aiming to produce more clinically informative preclinical data while reducing reliance on animal testing. The Switzerland-based company, with a significant financial and regulatory presence in the U.S., announced on October 7, 2026, that it is implementing New Approach Methodologies (NAMs)—a collection of non-animal techniques including cell-based assays and computational modeling—across its preclinical research.
The move matters because it could improve the translation of experimental findings to human biology, potentially increasing the odds of success in clinical trials. NAMs are aligned with FDA guidance and support the development of VERAXA’s BiTAC T-cell engagers, BiTAC-based antibody-drug conjugates, and bispecific antibody-drug conjugates for cancer treatment. According to the company, new three-dimensional spheroid data reinforce the ability of its models to assess the dual-target specificity of its lead T-cell engager candidates.
In an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, only about 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. This efficiency could enable faster iteration and cost savings in drug development.
For investors, the strategy may enhance VERAXA’s position as an emerging leader in designing novel cancer therapies. The company’s focus on human-relevant testing could also appeal to regulators and partners increasingly emphasizing ethical and predictive research methods. As VERAXA Biotech (NASDAQ: VRXA) advances its pipeline, the adoption of NAMs signals a commitment to innovation that may streamline preclinical workflows and reduce animal use. More details are available in the company’s newsroom at https://ibn.fm/VRXA.
MissionIR, a specialized communications platform, distributes news for VERAXA through its network. MissionIR is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. The platform also offers press release enhancement and social media distribution to maximize reach. These services help companies like VERAXA gain visibility among investors and the public.
